Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate

A method for suppressing food intake comprising administering to a subject in need thereof a composition, said composition comprising an insulinotropic peptide conjugate, which is prepared by linking an insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker,

• wherein the non-peptidyl linker is selected from the group consisting of succinimidyl 4-(N-maleimido-methyl)cyclohexane-l-carboxylate, succinimidyl 4-formylbenzoate, polyethylene glycol, polypropylene glycol, polyvinylpyrrolidone, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers such as polylactic acid and polylactic-glycolic acid, lipid polymers, chitins, hyaluronic acid, and combinations thereof;
• and
• wherein the insulinotropic peptide is imidazo-acetyl exendin-4 where the alpha carbon of the N-terminal histidine residue is deleted.

A method for reducing body fat or plasma cholesterol comprising administering to a subject in need thereof a composition, wherein the composition comprising an insulinotropic peptide conjugate, which is prepared by linking an insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker,

• wherein the non-peptidyl linker is selected from the group consisting of succinimidyl 4-(N-maleimido-methyl)cyclohexane-l-carboxylate, succinimidyl 4-formylbenzoate, polyethylene glycol, polypropylene glycol, polyvinylpyrrolidone, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers such as polylactic acid and polylactic-glycolic acid, lipid polymers, chitins, hyaluronic acid, and combinations thereof;
• and
• wherein the insulinotropic peptide is imidazo-acetyl exendin-4 where the alpha carbon of the N-terminal histidine residue is deleted.